Technologies Direct Biologics

Direct Biologics Granted Expanded Access By Fda For Exofloв ў In The Innovations in cellular communication discover the newest generation of naturally bioactive products for regenerative therapies. direct biologics offers a platform of regenerative products, including extracellular vesicles and placental based allografts. direct biologics is a market leading innovator and cgmp manufacturer of regenerative biologic products, including exoflo™, a covid 19. Direct biologics evs contain paracrine signals that assist with local cell to cell communication. they induce changes in nearby cells that create the appropriate healing environment and aid in tissue repair. stem and progenitor cells by nature work to heal, repair, and restore the body. in some cases where there is a chronic abnormality, these.

Technologies Direct Biologics Direct biologics, a regenerative biotechnology company with a groundbreaking extracellular vesicle (ev) platform technology, announced today that the fda has approved the company to proceed with its phase 3 clinical trial using its investigational ev drug, exoflo, to treat acute respiratory distress syndrome (ards) due to covid 19. Austin, texas, april 26, 2022 prnewswire direct biologics, a regenerative biotechnology company with a groundbreaking extracellular vesicle (ev) platform technology, announced today that the. The company was created to expand the science of cutting edge biologic technologies. direct biologic's management team holds extensive collective experience in biologics research, development, and. The us food and drug administration (fda) has granted regenerative medicine advanced therapy (rmat) designation to direct biologics’ extracellular vesicle (ev) drug product, exoflo, to treat covid 19 linked acute respiratory distress syndrome (ards). created using the company’s ev platform technology, exoflo is an acellular human bone.